31 related articles for article (PubMed ID: 7657535)
1. The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer.
Jiang G; Wang H; Huang D; Wu Y; Ding W; Zhou Q; Ding Q; Zhang N; Na R; Xu K
Front Oncol; 2021; 11():752860. PubMed ID: 34671562
[TBL] [Abstract][Full Text] [Related]
2. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information.
Popov Z; Gil-Diez de Medina S; Lefrere-Belda MA; Hoznek A; Bastuji-Garin S; Abbou CC; Thiery JP; Radvanyi F; Chopin DK
Br J Cancer; 2000 Jul; 83(2):209-14. PubMed ID: 10901372
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of invasive and noninvasive variants of a rat bladder tumor cell line.
Nishi N; Inui M; Kishi Y; Miyanaka H; Wada F
Jpn J Cancer Res; 1997 Sep; 88(9):831-8. PubMed ID: 9369930
[TBL] [Abstract][Full Text] [Related]
4. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.
Bringuier PP; Umbas R; Schaafsma HE; Karthaus HF; Debruyne FM; Schalken JA
Cancer Res; 1993 Jul; 53(14):3241-5. PubMed ID: 8324734
[TBL] [Abstract][Full Text] [Related]
5. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.
Morton RA; Ewing CM; Nagafuchi A; Tsukita S; Isaacs WB
Cancer Res; 1993 Aug; 53(15):3585-90. PubMed ID: 8339265
[TBL] [Abstract][Full Text] [Related]
6. Expression of E-cadherin and alpha-,beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors?
Mialhe A; Louis J; Montlevier S; Peoch M; Pasquier D; Bosson JL; Rambeaud JJ; Seigneurin D
Invasion Metastasis; 1997; 17(3):124-37. PubMed ID: 9702939
[TBL] [Abstract][Full Text] [Related]
7. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
8. Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms.
Giroldi LA; Bringuier PP; Schalken JA
Invasion Metastasis; 1994-1995; 14(1-6):71-81. PubMed ID: 7657535
[TBL] [Abstract][Full Text] [Related]
9. Classical cadherins in urological cancers.
Giroldi LA; Shimazui T; Schalken JA; Yamasaki H; Bringuier PP
Morphologie; 2000 Jun; 84(265):31-8. PubMed ID: 11048296
[TBL] [Abstract][Full Text] [Related]
10. [Cadherins in malignancies of the female genital tract].
Piura B; Rabinovich A; Aizenberg N; Wolfson M
Harefuah; 2005 Apr; 144(4):261-5, 303, 302. PubMed ID: 15889610
[TBL] [Abstract][Full Text] [Related]
11. Downregulation in vivo of the invasion-suppressor molecule E-cadherin in experimental and clinical cancer.
Mareel M; Vleminckx K; Vermeulen S; Yan G; Bracke M; van Roy F
Princess Takamatsu Symp; 1994; 24():63-80. PubMed ID: 8983064
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
